VKTX
HEALTHCAREViking Therapeutics Inc
$32.28+0.97 (+3.10%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VKTX Today?
No stock-specific AI insight has been generated for VKTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$22.96$43.15
$32.28
Fundamentals
Market Cap$3.7B
P/E Ratio—
EPS$-4.15
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.3M
Avg Volume (10D)—
Shares Outstanding116.1M
VKTX News
25 articles- Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026Yahoo Finance·May 5, 2026
- Here's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 MonthsMotley Fool·May 4, 2026
- Why Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And LossYahoo Finance·May 3, 2026
- VKTX Q1 Earnings Miss on Higher Phase 3 Development CostsYahoo Finance·Apr 30, 2026
- Viking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid ...Yahoo Finance·Apr 30, 2026
- Viking Therapeutics Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateYahoo Finance·Apr 29, 2026
- What is Driving a Strong Bullish Sentiment Towards Viking Therapeutics (VKTX)Yahoo Finance·Apr 29, 2026
- Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?Yahoo Finance·Apr 26, 2026
- This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall StreetMotley Fool·Apr 26, 2026
- Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom?The Motley Fool·Apr 25, 2026
- Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key InsightsYahoo Finance·Apr 23, 2026
- Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026Yahoo Finance·Apr 22, 2026
- Obesity Drugs Covered In Medicare Change. Questions Remain For Lilly, Novo.Yahoo Finance·Apr 22, 2026
- How CVS And Amazon Chipped Away At Eli Lilly, Novo Nordisk StocksYahoo Finance·Apr 21, 2026
- Viking Therapeutics Gears Up for Q1 Earnings: Here's What to ExpectYahoo Finance·Apr 21, 2026
- How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q1 Results?Yahoo Finance·Apr 20, 2026
- Assessing Viking Therapeutics (VKTX) Valuation As Obesity Trial Optimism Meets Richer Balance Sheet RatiosYahoo Finance·Apr 20, 2026
- Better Long-Term Buy: Eli Lilly or Viking Therapeutics?Motley Fool·Apr 17, 2026
- LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes StudyYahoo Finance·Apr 17, 2026
- Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?The Motley Fool·Apr 17, 2026
- Viking Therapeutics to Participate at Upcoming Investor ConferencesBenzinga·Apr 10, 2026
- Where Will Viking Therapeutics Stock Be in 10 Years?The Motley Fool·Apr 3, 2026
- 1 Reason This Biotech Stock Could Triple Before Year-EndThe Motley Fool·Mar 29, 2026
- Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735Benzinga·Mar 26, 2026
All 25 articles loaded
Price Data
Open$31.47
Previous Close$31.31
Day High$32.33
Day Low$31.17
52 Week High$43.15
52 Week Low$22.96
52-Week Range
$22.96$43.15
$32.28
Fundamentals
Market Cap$3.7B
P/E Ratio—
EPS$-4.15
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume2.3M
Avg Volume (10D)—
Shares Outstanding116.1M
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—